VSee Health (VSEE) director reports multiple stock awards as fees

Rhea-AI Filing Summary

VSee Health, Inc. (VSEE) director Colin P. O’Sullivan reported multiple stock awards of common stock as non-employee director compensation. On September 19, 2025, he acquired several blocks of common stock under the company’s 2024 Incentive Plan, with transaction code "A" indicating grants rather than open-market purchases or sales.

The reported awards include grants such as 21,870 shares at $0.69 per share and smaller blocks including 12,931 shares at $1.16, 12,500 shares at $1.20, 11,029 shares at $1.36, 10,067 shares at $1.49, and 227 shares at $2.31 per share. Footnotes state these shares were issued for O’Sullivan’s service as a director for quarters ended June 30, 2024 through September 30, 2025, based on the respective closing prices on specified dates.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'SULLIVAN COLIN P.

(Last) (First) (Middle)

C/O VSEE HEALTH, INC.

980 N FEDERAL HWY #304

(Street)

BOCA RATON FL 33432

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VSEE HEALTH, INC. [ VSEE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	09/19/2025		A		21,870	A	$0.69(1)	68,624	D
Common Stock, par value $0.0001 per share	09/19/2025		A		12,931	A	$1.16(2)	46,754	D
Common Stock, par value $0.0001 per share	09/19/2025		A		12,500	A	$1.2(3)	33,823	D
Common Stock, par value $0.0001 per share	09/19/2025		A		11,029	A	$1.36(4)	21,323	D
Common Stock, par value $0.0001 per share	09/19/2025		A		10,067	A	$1.49(5)	10,294	D
Common Stock, par value $0.0001 per share	09/19/2025		A		227	A	$2.31(6)	227	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended September 30, 2025. The number of shares issued to the reporting person is based on the closing price of the common stock on September 22, 2025.

2. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended June 30, 2025. The number of shares issued to the reporting person is based on the closing price of the common stock on June 30, 2025.

3. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended March 31, 2025. The number of shares issued to the reporting person is based on the closing price of the common stock on March 31, 2025.

4. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended December 31, 2024. The number of shares issued to the reporting person is based on the closing price of the common stock on December 31, 2024.

5. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended September 30, 2024. The number of shares issued to the reporting person is based on the closing price of the common stock on September 30, 2024.

6. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended June 30, 2024. The number of shares issued to the reporting person is based on the closing price of the common stock on July 30, 2025.

	/s/ Colin P. O'Sullivan	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did VSee Health (VSEE) report for Colin P. O’Sullivan?

VSee Health reported that director Colin P. O’Sullivan acquired multiple blocks of common stock on September 19, 2025 under transaction code "A", reflecting stock awards rather than sales.

How many VSee Health shares were granted in the largest single award to Colin P. O’Sullivan?

The largest individual award disclosed was 21,870 shares of VSee Health common stock at a price of $0.69 per share.

What is the source of the stock awards reported by the VSee Health director?

The stock awards were issued under VSee Health’s 2024 Incentive Plan in line with the company’s non-employee director compensation policy.

Which service periods do these VSee Health director stock awards cover?

Footnotes state the grants compensate service as a director for quarters ended September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025, as well as June 30, 2024.

Were the VSee Health director’s reported holdings recorded as direct or indirect ownership?

The transactions show ownership form as Direct (D), indicating the shares are directly held by Colin P. O’Sullivan.

How were the number of VSee Health shares for each director grant determined?

According to the footnotes, the number of shares issued for each quarter was based on the closing price of the common stock on specific dates such as September 22, 2025 and June 30, 2025.